Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

Nature Medicine

Volumn 8, Issue 10, 2002, Pages 1129-1135

  Launay, J M ^a   Herve P ^b   Peoc'h K ^a   Tournois, C ^a   Callebert, J ^a   Nebigil, C G ^c   Etienne, N ^c   Drouet, L ^a   Humbert, M ^d   Simonneau, G ^d   Maroteaux, L ^c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; ELASTASE; SEROTONIN 2 AGONIST; SEROTONIN 2B RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HYPOXIA; LUNG ARTERY PRESSURE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION;

ANIMALS; ANOXIA; BLOOD PRESSURE; CELL DIVISION; DEXFENFLURAMINE; DISEASE MODELS, ANIMAL; DNA; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MICE; ORGAN CULTURE TECHNIQUES; PULMONARY ARTERY; PYRIMIDINES; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; VASOCONSTRICTION;

ANIMALIA;

EID: 0036799278     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm764     Document Type: Article

References (46)

1. Rabinovitch, M. Pulmonary hypertension: updating a mysterious disease. Cardiovasc. Res. 34, 268-272 (1997).
2. Rubin, L.J. Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Pediatr. Pulmonol. Suppl. 18, 194-197 (1999).
3. Loscalzo, I. Genetic clues to the cause of primary pulmonary hypertension. N. Engl. J. Med. 345, 367-371. (2001).
4. Tucker, A. & Rhodes, I. Role of vascular smooth muscle in the development of high altitude pulmonary hypertension: an interspecies evaluation. High Alt. Med. Biol. 2, 173-189. (2001).
5. MacLean, M.R., Hervé, P., Eddahibi, S. & Adnot, S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br. J. Pharmacol. 131, 161-168. (2000).
6. Michelakis, E.D. & Weir, E.K. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am. J. Med. Sci. 321, 292-299. (2001).
7. Egermayer, P., Town, G.I. & Peacock, A.J. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 54, 161-168. (1999).
8. Hervé, P. et al. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 99, 249-254 (1995).
9. Kéreveur, A. et al. High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (Prostacyclin) therapy. Arterioscler. Thromb. Vasc. Biol. 20, 2233-2239 (2000).
10. Ullmer, C., Schmuck, K., Kalkman, H.O. & Lübbert, H. Expression of serotonin receptor mRNA in blood vessels. FEBS Lett. 370, 215-221 (1995).
11. Rich, S., Rubin, L., Walker, A.M., Schneeweiss, S. & Abenhaim, L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117, 870-874 (2000).
12. Abenhaim, L. et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 335, 609-616 (1996).
13. Fitzgerald, L.W. et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57, 75-81 (2000).
14. Launay, J.-M. et al. Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J. Biol. Chem. 271, 3141-3147 (1996).
15. Nebigil, C.G., Launay, J.-M., Hickel, P., Tournois, C. & Maroteaux, L. 5-Hydroxytryptamine 2B receptor regulates cell-cycle progression: Cross talk with tyrosine kinase pathways. Proc. Natl. Acad. Sci. USA 97, 2591-2596 (2000).
16. Ullmer, C., Boddeke, H.G.W.M., Schmuck, K. & Lübbert, H. 5-HT2B receptor-mediated calcium release from ryanodine-sensitive intracellular stores in human pulmonary artery endothelial cells. Br. J. Pharmacol. 117, 1081-1088 (1996).
17. Glusa, E. & Pertz, H.H. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT2B receptors. Br. J. Pharmacol. 130, 692-698 (2000).
18. Nebigil, C.G. et al. 5erotonin 2B receptor is required for heart development. Proc. Natl. Acad. Sci. USA 97, 9508-9513 (2000).
19. Nebigil, C.G. et al. Ablation of serotonin 5-HT2B receptors in mice leads to abnormal cardiac structure and function. Circulation 103, 2973-2979 (2001).
20. Bonhaus, D.W. et al. R5-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br. J. Pharmacol. 127, 1075-1082 (1999).
21. Belknap, J.K., Orton, E.C., Ensley, B., Tucker, A. & Stenmark, K.R. Hypoxia increases bromodeoxyuridine labeling indices in bovine neonatal pulmonary arteries. Am. J. Respir. Cell. Mol. Biol. 16, 366-371 (1997).
22. Rabinovitch, M. EVE and beyond, retro and prospective insights. Am. J. Physiol. 277, L5-12. (1999).
23. Vu, T.H. & Werb, Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 14, 2123-2133. (2000).
24. MacLean, M.R. Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action? Trends Pharmacol. Sci. 20, 490-495 (1999).
25. Eddahibi, S., Raffestin, B., Launay, J.M., Sitbon, M. & Adnot, S. Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia. Am. J. Respir. Crit. Care Med. 157, 1111-1119 (1998).
26. Eddahibi, S. et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 105, 1555-1562 (2000).
27. Steudel, W. et al. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J. Clin. Invest. 101, 2468-2477 (1998).
28. Hoshikawa, Y. et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am. J. Respir. Crit: Care Med. 164, 314-318. (2001).
29. Keegan, A., Morecroft, I., Smillie, D., Hicks, M.N. & MacLean, M.R. Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension. Converging evidence using S-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935. Circ. Res. 89, 1231-1229 (2001).
30. Rabinovitch, M. Problems of pulmonary hypertension in children with congenital cardiac defects. Chest 93, 119S-126S. (1988).
31. Zhao, L., Long, L., Morrell, N.W. & Wilkins, M.R. NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 99, 605-607 (1999).
32. Buczko, W., De Gaetano, G. & Garattini, S. Effect of fenfluramine on 5-hydroxytryptamine uptake and release by rat blood platelets. Br. J. Pharmacol. 53, 563-359 (1975).
33. Rothman, R.B. et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-2841. (2000).
34. Humbert, M. et al. Pulmonary arterial hypertension and type-I glycogen-storage disease: The serotonin hypothesis. Eur. Respir. J. 20, 59-65 (2002).
35. Naeije, R., Maggiorini, M., Delcroix, M., Leeman, M. & Melot, C. Effects of chronic dexfenfluramine treatment on pulmonary hemodynamics in dogs. Am. J. Respir. Crit. Care Med. 154, 1347-1350. (1996).
36. Eddahibi, S. et al. Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J. Pharmacol. Exp. Ther. 297, 148-154. (2001).
37. Eddahibi, S. et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 108, 1141-1150. (2001).
38. Rabinovitch, M. Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension. Clin. Invest. 108, 1109-1111. (2001).
39. Fanburg, B.L. & Lee, S.L. A new role for an old molecule: serotonin as a mitogen. Am. J. Physiol. 272, L795-806 (1997).
40. Lee, S.L., Wang, W.W., Finlay, G.A. & Fanburg, B.L. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am. J. Physiol. 277, L282-291 (1999).
41. Pitt, B.R. et al. Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture. Am. J. Physiol. 266, L178-186 (1994).
42. Sanchez, C. & Hyttel, I. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19, 467-489 (1999).
43. Cowan, K.N. et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nature Med. 6, 698-702 (2000).
44. Morrell, N.W. et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 104, 790-795. (2001).
45. Cowan, K.N., Jones, P.L. & Rabinovitch, M. Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ. Res. 84, 1223-1233. (1999).
46. Midha, K.K. et al. The identification of two new urinary metabolites of fenfluramine in man. Xenobiotica 13, 31-38. (1983).